Our technology is based on a proprietary modification of Taylor-Couette-Poiseuille (TCP) flow. While the technology was initially explored for hydrogen gas production, exploratory research in other areas revealed promising effects and we shifted our research focus to biological systems. Our lead drug candidate, RNS60, has shown significant efficacy in multiple models of neurodegenerative diseases.

Due to the unique requirements for the formulation and filling of TCP based compounds we designed, built, and commissioned our own GMP qualified facility with semi-automated, aseptic manufacturing capabilities for inhaled and parenteral investigational new drugs.